TipRanks
Advertisement
Advertisement
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing
PremiumCompany AnnouncementsKorro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing
2M ago
Korro Bio Advances KRRO-121 Into First Human Trial
Premium
Company Announcements
Korro Bio Advances KRRO-121 Into First Human Trial
2M ago
Buy Rating Reiterated on Strong Pipeline Progress and Clinical Catalysts; $21 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on Strong Pipeline Progress and Clinical Catalysts; $21 Price Target Unchanged
2M ago
JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
PremiumThe FlyJonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
5M ago
Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
Premium
The Fly
Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
6M ago
Korro Bio files to sell 7.65M shares of common stock for holders
Premium
The Fly
Korro Bio files to sell 7.65M shares of common stock for holders
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―